Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.37 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 5/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | CTSG | P08311 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1343847 | 1.00 | FAAH (0.41) | FAAHPARP1KLK7PLA2G10PLA2G5 | |
| SCHEMBL1343846 | 1.00 | FAAH (0.41) | FAAHPARP1KLK7PLA2G10PLA2G5 | |
| SCHEMBL1341573 | 0.91 | PARP1 (0.40) | PARP1KLK7PLA2G10PLA2G5STS | |
| SCHEMBL1341574 | 0.91 | PARP1 (0.40) | PARP1KLK7PLA2G10PLA2G5STS | |
| SCHEMBL1345008 | 0.91 | PARP1 (0.40) | PARP1KLK7PLA2G10PLA2G5STS | |
| SCHEMBL1342920 | 0.83 | NPC1 (0.41) | PARP1KLK7TEAD3L3MBTL1 | |
| SCHEMBL1344901 | 0.83 | NPC1 (0.41) | PARP1KLK7TEAD3L3MBTL1 | |
| SCHEMBL1342916 | 0.83 | NPC1 (0.41) | PARP1KLK7TEAD3L3MBTL1 | |
| SCHEMBL1341565 | 0.76 | FAAH (0.35) | FAAHPLA2G10PLA2G5MGLL | |
| SCHEMBL1343824 | 0.76 | FAAH (0.35) | FAAHPLA2G10PLA2G5MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063042-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2220055-A2 | NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-08-25 | — | — | EP | disclosed |
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2009-01-22 | — | — | US | disclosed |
| WO-2009010429-A2 | NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | CCR5, CCR3, CCR2 | FAAH 2254/4885PARP1 1841/4885KLK7 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.